Eupraxia Reports Positive EP-104GI Clinical Data; Strengthens Team

Eupraxia Pharmaceuticals announced its second quarter 2026 financial results, reporting a net loss of $14.5 million, an increase from $8.7 million in the prior year, primarily due to increased R&D costs. The company maintains a strong financial position with $133.6 million in cash and short-term investments, projected to fund operations into the second half of 2028. Operationally, Eupraxia presented positive data for EP-104GI at Digestive Disease Week, demonstrating improvement in fibrosis and inflammation in Eosinophilic Esophagitis (EoE) patients, with 66% achieving clinical remission in symptoms at week 36. The executive team and Board were also strengthened with key appointments to bolster late-stage drug development and global commercialization capabilities.